Industry groups are looking to push government drug price negotiation and PBM reforms into a massive Republican domestic ...

Biotech investing saw growth in 2024, with RA Capital leading VCs. FDA cancels flu vaccine meeting, Pfizer hires ex-FDA ...

Praxis reported that its lead small molecule program failed a Phase 3 study on Friday morning, sending its stock price down ...

CHMP recommends approval of Regeneron's Lynozyfic, Krystal's Vyjuvek, Accord's trabectedin, Takeda's Deqsiga, and 16 label ...

William Pao, former Roche R&D leader and Pfizer CDO, now leads Revelio Therapeutics (formerly Launchpad) as CEO, joins ...

More than a month after its most recent scheduled meeting was postponed, a panel advising the government on a federal ...

Vertex Pharmaceuticals exits liver disease gene editing program with Verve Therapeutics. Verve continues work on a separate ...

Kallyope's Phase 2 obesity trial shows K-757 and K-833 combo achieved 2.9% weight loss vs 0.2% for placebo. Results fall ...

RA Capital leads as most active venture player in private biotech rounds through 2024, with ARCH participating in fewer but ...

Something changed for Bill Anderson when he turned 50. He was ascending the ranks of Roche’s Genentech, but the Texas native ...

Sorriso Pharmaceuticals presents Phase 1b data for SOR102, an oral bispecific antibody for IBD, showing 40% endoscopic ...

Medicare use of GLP-1 diabetes drugs like Ozempic rose 900% over 5 years, with 2023 spending at $35.8B. HHS report shows ...